"10.1371_journal.pone.0022003","plos one","2011-07-19T00:00:00Z","Sandra Mathis; Bettina Khanlari; Federico Pulido; Mauro Schechter; Eugenia Negredo; Mark Nelson; Pietro Vernazza; Pedro Cahn; Jean-Luc Meynard; Jose Arribas; Heiner C Bucher","Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland; Division of Infectious Diseases and Hospital Hygiene, University Hospital Basel, Basel, Switzerland; HIV Unit, Hospital 12 de Octubre, i+12, Universidad Complutense de Madrid, Madrid, Spain; Departement de Medicina Preventiva da Facultade de Medicina, Universida Federal do Rio de Janeiro, Rio de Janeiro, Brasil; Fundació Lluita Contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Chelsea and Westminster Hospital, London, United Kingdom; Division of Infectious Diseases, Kantonsspital St. Gallen, St. Gallen, Switzerland; Fundacion Huesped, Buenos Aires, Argentina; Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France; Servicio de Medicina Interna, Hospital la Paz, Universidad Autonoma de Madrid, IdiPAZ, Madrid, Spain","Conceived and designed the experiments: SM BK HCB. Performed the experiments: SM BK HCB. Analyzed the data: SM BK HCB. Contributed reagents/materials/analysis tools: FP MS EN MN PV PC JLM JA. Wrote the paper: SM HCB. ICMJE criteria for authorship: SM BK HCB FP MS EN PV MN PC JLM JA. Results and conclusions: SM HCB FP JA. Enrolled patients: FP MS EN PV MN PC JLM JA. Full access to data in the study and responsibility for the integrity of the data and the accuracy of the data analysis: HCB. Critical revision of the manuscript for important intellectual content: SM BK FP MS EN MN PV PC JLM JA HCB. Statistical analysis: SM HCB. Obtained funding: HCB. Study supervision: HCB.","Heiner C. Bucher has received travel grants, honoraria and unrestricted research grants from GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Roche, Abbott, Tibotec, Boehringer-Ingelheim and ViiV Healthcare. Federico Pulido has received consulting and lecture fees from Abbott, Bristol- Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, and Roche. Pietro Vernazza has received travel grants and honoraria from GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Abbott, Tibotec, and Boehringer-Ingelheim. Jose Arribas received grant research support, advisory and speaker fees from Abbott, Gilead, ViiV Healthcare, Tibotec, Janssen, Roche and Bristol-Myers Squibb. Pedro Cahn has served as advisory board member for Avexa, Gilead, GlaxoSmithKline, Myriad, Merck, Pfizer, Pharmasset, Schering Plough, and Tibotec. He has served as an investigator for Avexa, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Roche, Merck, Pfizer, Pharmasset, Schering Plough, Tibotec, Abbott, and Bristol-Myers Squibb. He has served as a speaker (content and design performed by the speaker, no company control) at meetings organized by Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, and Tibotec. He has served as a scientific advisor for Merck Sharp & Dohme, Pfizer, GlaxoSmithKline, Avexa and Tibotec. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","07","Sandra Mathis","SM",11,TRUE,3,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
